@prefix jvr: <http://data.loterre.fr/ark:/67375/JVR> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix mesh: <http://id.nlm.nih.gov/mesh/vocab#> .
@prefix dc: <http://purl.org/dc/terms/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .

jvr:-BT300B3G-Q
  skos:prefLabel "cerebrospinal fluid (Qualifier)"@en, "liquide cérébrospinal (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-DNJSW0D3-M
  skos:prefLabel "Alcohol Deterrents"@en, "Substances à effet antabuse"@fr ;
  a mesh:Descriptor, skos:Concept .

jvr:-L6C0XPHT-4
  skos:prefLabel "métabolisme (Qualificatif)"@fr, "metabolism (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-XV06LPML-W
  skos:prefLabel "urine (Qualifier)"@en, "urine (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-Z3S7C686-0
  mesh:allowableQualifier jvr:-G30ZJ446-J, jvr:-Q3979798-W, jvr:-WK5F724J-1, jvr:-S0CS1X5R-5, jvr:-XV06LPML-W, jvr:-R0ZCQ8X6-J, jvr:-NKM836P1-M, jvr:-FWD2BGQ0-9, jvr:-M63HSDM7-1, jvr:-BT300B3G-Q, jvr:-H7K65Q8S-Z, jvr:-NB0XHT3S-N, jvr:-THHNVC7V-3, jvr:-NHL3D2X0-S, jvr:-D0F21513-5, jvr:-G4R176S9-J, jvr:-NFTHND7Q-8, jvr:-TJHVZCRZ-0, jvr:-T9HQD7ST-J, jvr:-CB30NGKB-3, jvr:-R3QWLHRG-V, jvr:-HQRFT0C6-B, jvr:-W6SQV79N-S, jvr:-L6C0XPHT-4, jvr:-SBNWSM1T-R ;
  skos:altLabel "5S6W795CQM"@en, "5S6W795CQM"@fr, "16590-41-3 (Naltrexone)"@fr, "16590-41-3 (Naltrexone)"@en, "Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5alpha)-"@fr, "Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5alpha)-"@en, "Z6375YW9SF"@fr, "Z6375YW9SF"@en ;
  skos:inScheme jvr: ;
  skos:hiddenLabel "ReVia"@en, "EN-1639A"@fr, "EN-1639A"@en, "Trexan"@en, "Naltrexone Hydrochloride"@en, "Nemexin"@en, "Antaxone"@en, "Celupan"@en, "Chlorhydrate de naltrexone"@fr, "EN1639A"@fr, "Nalorex"@en ;
  skos:definition "Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence."@en ;
  dc:modified "2018-04-10"^^xsd:date ;
  a skos:Concept, mesh:Descriptor ;
  dc:created "1975-07-23"^^xsd:date ;
  skos:broader jvr:-P61NBRDQ-S ;
  skos:prefLabel "Naltrexone"@fr, "Naltrexone"@en ;
  dc:established "1986-01-01"^^xsd:date ;
  owl:sameAs <http://id.nlm.nih.gov/mesh/D009271> ;
  mesh:pharmacologicalAction jvr:-DNJSW0D3-M, jvr:-KQW1R3Q5-R .

jvr:-Q3979798-W
  skos:prefLabel "analysis (Qualifier)"@en, "analyse (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-H7K65Q8S-Z
  skos:prefLabel "radiation effects (Qualifier)"@en, "effets des radiations (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-TJHVZCRZ-0
  skos:prefLabel "administration et posologie (Qualificatif)"@fr, "administration & dosage (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-G30ZJ446-J
  skos:prefLabel "toxicity (Qualifier)"@en, "toxicité (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-NFTHND7Q-8
  skos:prefLabel "intoxication (Qualificatif)"@fr, "poisoning (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-FWD2BGQ0-9
  skos:prefLabel "usage thérapeutique (Qualificatif)"@fr, "therapeutic use (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-THHNVC7V-3
  skos:prefLabel "synthèse chimique (Qualificatif)"@fr, "chemical synthesis (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-R0ZCQ8X6-J
  skos:prefLabel "agonistes (Qualificatif)"@fr, "agonists (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-S0CS1X5R-5
  skos:prefLabel "immunology (Qualifier)"@en, "immunologie (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-M63HSDM7-1
  skos:prefLabel "antagonists & inhibitors (Qualifier)"@en, "antagonistes et inhibiteurs (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-HQRFT0C6-B
  skos:prefLabel "isolement et purification (Qualificatif)"@fr, "isolation & purification (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-NB0XHT3S-N
  skos:prefLabel "adverse effects (Qualifier)"@en, "effets indésirables (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-W6SQV79N-S
  skos:prefLabel "classification (Qualifier)"@en, "classification (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-CB30NGKB-3
  skos:prefLabel "economics (Qualifier)"@en, "économie (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-G4R176S9-J
  skos:prefLabel "analogs & derivatives (Qualifier)"@en, "analogues et dérivés (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr: a skos:ConceptScheme .
jvr:-SBNWSM1T-R
  skos:prefLabel "history (Qualifier)"@en, "histoire (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-P61NBRDQ-S
  skos:prefLabel "Naloxone"@fr, "Naloxone"@en ;
  a mesh:Descriptor, skos:Concept ;
  skos:narrower jvr:-Z3S7C686-0 .

jvr:-D0F21513-5
  skos:prefLabel "chemistry (Qualifier)"@en, "composition chimique (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-R3QWLHRG-V
  skos:prefLabel "standards (Qualifier)"@en, "normes (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-NHL3D2X0-S
  skos:prefLabel "sang (Qualificatif)"@fr, "blood (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-T9HQD7ST-J
  skos:prefLabel "ressources et distribution (Qualificatif)"@fr, "supply & distribution (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-KQW1R3Q5-R
  skos:prefLabel "Antagonistes narcotiques"@fr, "Narcotic Antagonists"@en ;
  a mesh:Descriptor, skos:Concept .

jvr:-NKM836P1-M
  skos:prefLabel "pharmacology (Qualifier)"@en, "pharmacologie (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-WK5F724J-1
  skos:prefLabel "pharmacokinetics (Qualifier)"@en, "pharmacocinétique (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .